Hairy, it's all pre-programmed buy-sell by hedgies in cooperation with the MM!! And, the mon.....key traders just dancing around to make easy money!! Like ms wardcleaver states below, the net SP IS moving up. Hedgies and traders like to make at least a few pennies a share a day and sleep resfully at night!! This is the modern-day market where those who are lazy bums to do anything constructive and meaningful have found a way to make their living!! Politicians love it!!!!
Scott, I do not think Geron will get back into the stem-cell or regeneration business. It will concentrate on development of compounds for application in oncology. If you do not know, Dr. West, the current CEO of BioTime, the parent company of Asteria, was at Geron and, I think, the Geron board decided to give the gift to him by selling the stem-cell assets cheap to him. In my view, it was all a ploy at the cost of Geron shareholders.
Well, type the name on Google and check his background. I did not do that but, based on the plan he has developed, he sure seems to be a dynamic guy and apparently liked by WS. I divested fully from AST and threw the money in Ocata because I see its RPE product has a better chance of success much sooner and Ocata may be in the process of getting into a partnership like Geron. WS just seems to have expectation of a breakthrough medical system using hPSCs; but, I think AST's OPC1 may be years away from licensing as side-effects evaluation will be very time-consuming, whereas the retinal use of RPE cells will not have that trouble because the cells do not go farther than the retinal area. Lichtinger is simply hyping, apparently effectively, perhaps to jack up the SP so that he can squeeze more money from WS when he goes out for an offering. Ocata's Ph1 found no side effect and it did find significant effectiveness even in Ph 1. I expect success in its Ph 2 and Ph 3 and even a grant of FTD. Of course, my views!!
The new CEO Pedro Lichtinger appears to be much more dynamic than Okarma and is certainly more effective. My concern is that its burn rate is currently $6M per quarter and once the OPC1 trial is more active it will shoot up. Where is it going to get the money to fund all those activities they have planned? New offering must be in consideration. Then, there will be dilutions, perhaps several, during the rest of 2015 and 2016. We will have to see how Lichtinger handles that aspect. The 1$4M total grant from CIRM will last just for two quarters and will not be available fully so soon!! In any case, Scarlett-Huh and company returned the 25M grant they received from CIRM with a hefty fine payment - at our cost, and placed the OPC1 trial on the shelf while negating the investment we shareholders made to develop those patents!! I am not sure if the Geron management did all that in the best interest of its shareholders. I have my fingers crossed
make_up, here on this board, your contention that man does not exploit man is questionable!! Vermin are vermin and they are present in a large mass here too!! Of course, they come and go when they find greener pasture somewhere else!!
Good and insightful post!! One major reason to augment your logic: IMET is potentially a BTD drug for hematological cancers and there is a pretty good chance that it will be used successfully in combination with other appropriate drugs for solid-tumor cancers. Of course, this onclogical arena will have a lot of competition, IMET should remain a top choice due to its telomere/telomerase base and its use will not have any serious side effect. And, with Janssen now in full charge of developing it, it will become a reality much faster. Celgene guys must be nervous and may be doubling up their efforts to beat IMET because Celgene has a lot at stake if IMET outdoes its drugs.
flock on any security that is in the news, like hundreds and thousands of ants running ad flocking on a relatively small piece of food on the ground!! And, just like ants pushing and fighting with each other to take a bite, these bundars, vermin and d...ogs try to beat each other by using whatever method they can use in their quest to make quick bucks!! I have a suggestion: They all should join our army and be sent to eradicate ISIS. That will be more meaningful and satisfying to themselvesin their lives. And, doing so, will free this board of all lies, inuendos and worthless posts, making room for some meaningful posts. God help them see that!!!
Stupid Yahoo (or my Explorer) did not post fully!! Anyhow, I ask readers to get my points based on what showed up. above. Thanks and thanks to Scistats to post a very important and pertinent fact which was pushed back by worthless posts from mon...keys and dogs!!! These vermin are a cancer to any board!!!
Ilike that IMET in combination with right chemical(s) can be made effective to several solid-tumor cancers. Thus, the future propspects for general use of IMET for most cancers seems likely. JNJ got a good deal!!! Looking at Cegene getting revenue in multiple billions of dollars a year making Celgene nervous!!
Good for you!! Now get a chilled beer and munch some brocolli!!! And, spend the 10% buying a new car to take your female friend around!!!
The last 10 minutes of bandars and dogs scrambling!! Real fun watching the tape!! people trying to make easy money!! They all will look for chilled beer after market closes!!!!!
Bandars is used for mon...keys because the latter is restricted by Yah!! All in all, they will have a good day if they got in early to-day. But, knowing their psychology, they can't part with their greed and, like fools, may still end up having a sour test in their mouth!!
To-day's SP and trading is still a "Barron's effect" as WS dogs just think it's an authentic source!! The bandars go by SA and theirhalf-hearted chart knowledge. MM is having fun making a bundle to-day!! What a money-crazy world where people seek easy money!! It's all fun watching bandars going up and down and the dogs barking while the MM dancing (with his pants off?)!!!
I am not sure if these semi-pundits apply their theory to PCYC and such other stocks in the Geron league for verification or not!! Again, the securities market was a much different and simpler animal 20 years back than now. These "chart experts" can't account for the boundary conditions changes!! And, yet, make statements like they know everything!! Their arrogance and ego often hurts none other than themselves. That reminds me of Will Durrant who stated, "One who knows knows what he knows and knows what he doesn't". A lot of these semi-pundits do not know what they do not know!!!
I am not sure if 615 compound is tied to IMET for that purpose and must not be a part of the IMET multi-application deal with Janssen. Geron must be holding all rights to it and may do further do research in developing it for an ultimate commercial use. If this substance proves successful, like IMET, in its Ph 1 trial, Geron may go into partnership deal with Janssen (if the IMET partnership brings no problems) or another major pharma. With $170M in hand and a staff of only 20 currently, Geron has enough money to hire more, just needed, right persons to do further work (including beginning a clinical trial) on 615 compound. I feel, too, that Scarlett is on his way out with a decent termination deal to make room for a right guy to take his place for the NEW Geron. These are my views and I too, like you, is not an expert on this! This is a Yahoo board where we exchange our views and not necessarily have to present data supporting our views as some half-smart guys may insist!!